Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock FBIOP 深滬

等待開盤 09-23 09:30:00 美东时间

17.15

-0.120

-0.69%

華盛通

立即下載

最高18.00
今開18.00
成交量 7327股
最低 17.10
昨收 17.27
總市值 5877.54万
52周最高 21.43
市盈率 ^靜 --
換手率 0.21%
52周最低 6.27
委比 57.93%
總股本 342.71万
歷史最高 21.43
量比 0.79
振幅 5.21%
歷史最低 -1.5766
每手 1
風險率 4.66%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Journey Medical Corporation (NASDAQ: DERM) announced that its CEO, Claude Maraoui, will attend two investor conferences in September 2026. The first is the Lake Street Capital Markets 10th Annual BIG10 Conference on September 10 in New York City, featuring 1x1 meetings. The second is the H.C. Wainwright 28th Annual Global Investment Conference on September 14, also in NYC, with a presentation and 1x1 meetings. A webcast of the H.C. Wainwright pre...

09-08 20:05
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Longeveron Inc. appoints Nirav Jhaveri as Chief Financial Officer, bringing over 25 years of experience in biotech finance and capital markets. Jhaveri succeeds Marie Washburn, who returns to her role as Corporate Controller. The company highlights Jhaveri's expertise in advancing stem cell therapy, particularly its lead product laromestrocel, which is in Phase 2b trials for HLHS. Jhaveri aims to support the company's growth and operational effic...

08-19 20:05
Fortress Biotech Q2 Earnings Preview

Fortress Biotech (FBIO) is scheduled to announce Q2 earnings results on Wednesday, August 12th, after market close. The consensus EPS Estimate is -$0.20 and the consensus Revenue Estimate is $18.3M (+...

08-12 05:35
Fortress Biotech’s Urica Therapeutics Says Crystalys Closes Oversubscribed $130M Series B Financing To Support Late-Stage Global Clinical Development And Commercialization Preparation For Dotinurad

Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc. ("Crystalys"), in which Urica maintains an equity position, closed an oversubscribed $130 million Series B financing to support the l...

07-27 20:03
Fortress Biotech Q1 EPS $2.82 Beats $(0.22) Estimate, Sales $16.038M Miss $16.338M Estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $2.82 per share which beat the analyst consensus estimate of $(0.22) by 1381.82 percent. This is a 687.5 percent increase over losses of $(0.48) per share

05-15 05:29
Fortress Biotech Q4 EPS $(0.30) Beats $(0.42) Estimate, Sales $16.079M Miss $21.018M Estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.42) by 28.57 percent. This is a 15.38 percent decrease over losses of $(0.26) per share from

04-01 05:19
Fortress Biotech And Cyprium Therapeutics Announce The Closing Of The Sale Of Cyprium's Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $205M

Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced the closing of the sale of Cyprium's Rare Pediatric Disease Priority Review

03-31 04:17
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech and its subsidiary Cyprium Therapeutics announce the sale of Cyprium’s Rare Pediatric Disease Priority Review Voucher for $205 million. Fortress, as the majority shareholder, expects to receive over $100 million, enhancing its financial flexibility. The transaction follows three FDA approvals in the past 15 months and the sale of Checkpoint Therapeutics. Cyprium will continue to earn royalties and milestones from ZYCUBO sales and...

03-30 20:05
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Journey Medical Corporation (Nasdaq: DERM), a pharmaceutical company focused on dermatological treatments, announced on March 18, 2026, that it will release its year-end 2025 financial results after U.S. markets close on March 25, 2026. A conference call and audio webcast will be held on March 25 at 4:30 p.m. ET to discuss the results and provide a corporate update. Participants can join by dialing 1-866-777-2509 (U.S.) or 1-412-317-5413 (interna...

03-18 12:30
HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $17 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $17 price target.

02-24 00:05

派息除權日	每股總股息	派息日期
2024-06-14	0.20	2024-06-30
2024-05-14	0.20	2024-05-31
2024-04-12	0.20	2024-04-30
2024-03-14	0.20	2024-03-31
2024-02-14	0.20	2024-02-29
2024-01-11	0.20	2024-01-31
2023-12-14	0.20	2023-12-31
2023-11-14	0.20	2023-11-30
2023-10-12	0.20	2023-10-31
2023-09-14	0.20	2023-09-30
2023-08-14	0.20	2023-08-31
2023-07-13	0.20	2023-07-31
2023-06-14	0.20	2023-06-30
2023-05-12	0.20	2023-05-31
2023-04-13	0.20	2023-04-30
2023-03-14	0.20	2023-03-31
2023-02-14	0.20	2023-02-28
2023-01-12	0.20	2023-01-31
2022-12-14	0.20	2022-12-31
2022-11-14	0.20	2022-11-30
2022-10-13	0.20	2022-10-31
2022-09-14	0.20	2022-09-30
2022-08-12	0.20	2022-08-31
2022-07-14	0.20	2022-07-31
2022-06-14	0.20	2022-06-30
2022-05-12	0.20	2022-05-31
2022-04-13	0.20	2022-04-30
2022-03-14	0.20	2022-03-31
2022-02-14	0.20	2022-02-28
2022-01-13	0.20	2022-01-31
2021-12-14	0.20	2021-12-31
2021-11-12	0.20	2021-11-30
2021-10-14	0.20	2021-10-30
2021-09-14	0.20	2021-09-30
2021-08-12	0.20	2021-08-30
2021-07-14	0.20	2021-07-30
2021-06-14	0.20	2021-06-30
2021-05-13	0.20	2021-05-30
2021-04-14	0.20	2021-04-30
2021-03-12	0.20	2021-03-31
2021-02-11	0.20	2021-02-28
2021-01-14	0.20	2021-01-31
2020-12-14	0.20	2020-12-31
2020-11-12	0.20	2020-11-30
2020-10-14	0.20	2020-10-31
2020-09-14	0.20	2020-09-30
2020-08-20	0.20	2020-08-31
2020-07-17	0.20	2020-07-31
2020-06-12	0.59	2020-06-30
2020-03-13	0.59	2020-03-31
2019-12-12	0.59	2019-12-31
2019-09-12	0.59	2019-09-30
2019-06-13	0.59	2019-07-01
2019-03-14	0.59	2019-03-31
2018-12-13	0.59	2018-12-31
2018-09-13	0.59	2018-09-30
2018-06-14	0.59	2018-06-30
2018-03-14	0.59	2018-03-30

公司名稱	Fortress Biotech, Inc.
行業分類	Pharmaceuticals: Major
業務描述	Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock FBIOP 深 滬

17.15

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock FBIOP 深滬